IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Onyx Biotec IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Solan and caters to Pharmaceutical sector. Horizon Management Private is the merchant banker of Onyx Biotec IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 5th August 2024.
Onyx Biotec IPO posted revenues of Rs 63.24 crores and PAT of Rs 7.80 crores in FY25 on annualised basis.Financial results of Onyx Biotec IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Onyx Biotec IPO PAT Margin is 12.43%, ROCE (Return on Capital Employed) is 10.58% as per latest financial. The below table shows Onyx Biotec IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Onyx Biotec IPO is Rs 110.61 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Onyx Biotec IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Onyx Biotec IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Onyx Biotec IPO is ₹110.61 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Onyx Biotec IPO has a Price-to-Earnings (PE) ratio of 14.10 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Onyx Biotec IPO reported revenue of ₹63.24 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Onyx Biotec IPO provide insights into sales growth, market demand, and business scalability.
Onyx Biotec recorded an EBITDA of ₹ 16.50 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Onyx Biotec Profit After Tax (PAT) is ₹7.86 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 63.24 Cr.
EBITDA Margin:
26.09
%
Net Worth: ₹ 26.19 Cr.
Market Capitalisation:
₹ 110.61 Cr.
P/E:
14.10 times
P/BV: 1.99 times
EV/EBITDA: 8.58 times
Onyx Biotec operates in Pharmaceutical and Pharmaceutical Company Providing Sterile Water For Injections. The Issue is listed on NSE EMERGE in Nov, 2024. Onyx Biotec IPO size was 29.34 with Issue price of 61.00 .
Merchant Banker(s) of Onyx Biotec IPO: Horizon Management Private Limited
Onyx Biotec IPO subscription was 198.00 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Onyx Biotec IPO listed at a listing price of 56.75 against the offer price of 61.00.
The current market price of Onyx Biotec is 50.00.
Why Us?
